Canagliflozin and Cardiovascular disease- results of the CANVAS trial

• Auteurs principaux: Syed Raza Shah (Auteur), Najla Issa Najim (Auteur), Zainab Abbasi (Auteur), Mazia Fatima (Auteur), Ayesha Altaf Jangda (Auteur), Waqas Shahnawaz (Auteur), Maira Shahid (Auteur), Syed Arbab Shah (Auteur)
• Format: Livre
• Publié: Greater Baltimore Medical Center, 2018-09-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to reduction in plasma glucose concentration, in...